MedMatrix Rx
Daily 340B Morning Briefing for Executives
The 340B landscape remains dynamic with significant developments in litigation and federal policy. A federal judge decertified 11 clinics from the 340B program, siding with drugmakers. Meanwhile, NASP submitted comments on CMS’ proposed 340B payment changes, and the AHA urged CMS to reconsider its 2027 outpatient rule proposals. AstraZeneca and other drugmakers continue to challenge state 340B laws in court. This shows ongoing tensions between manufacturers and covered entities.
EXECUTIVE SUMMARY
01
Federal judge decertifies 11 clinics from 340B program.
A federal judge ordered the decertification of 11 clinics from the 340B program, siding with drugmakers like Amgen and Genentech.
A federal judge ordered the decertification of 11 clinics from the 340B program, siding with drugmakers like Amgen and Genentech.
Source: Becker’s Hospital Review
02
NASP comments on CMS’ proposed 340B payment changes.
NASP submitted comments on CMS’ CY 2027 HOPPS proposed rule, focusing on 340B reimbursement changes and implications for specialty pharmacy services.
NASP submitted comments on CMS’ CY 2027 HOPPS proposed rule, focusing on 340B reimbursement changes and implications for specialty pharmacy services.
Source: NASP
03
Milwaukee hospital sues CVS over alleged 340B diversion.
Froedtert Memorial Lutheran Hospital filed a lawsuit against CVS Health, alleging $18 million in 340B diversion between 2020 and 2025.
Froedtert Memorial Lutheran Hospital filed a lawsuit against CVS Health, alleging $18 million in 340B diversion between 2020 and 2025.
Source: Becker’s Hospital Review
04
AHA urges CMS to reconsider 2027 outpatient rule proposals.
AHA urged CMS not to finalize proposals that would increase Medicare payment clawbacks and cut 340B drug reimbursement rates.
AHA urged CMS not to finalize proposals that would increase Medicare payment clawbacks and cut 340B drug reimbursement rates.
Source: Becker’s Hospital Review
05
AstraZeneca challenges Illinois’ 340B law in federal court.
AstraZeneca sued Illinois over a new 340B contract pharmacy law, arguing it is preempted by federal law and unconstitutional.
AstraZeneca sued Illinois over a new 340B contract pharmacy law, arguing it is preempted by federal law and unconstitutional.
Source: Becker’s Hospital Review
06
Hospital groups oppose CMS’ 2027 outpatient proposed rule.
AHA, AAMC, and AMGA submitted comments urging CMS to withdraw or scale back key provisions of the 2027 outpatient proposed rule.
AHA, AAMC, and AMGA submitted comments urging CMS to withdraw or scale back key provisions of the 2027 outpatient proposed rule.
Source: Becker’s Hospital Review
07
HRSA revises 340B Rebate Model Pilot Program.
HRSA published a revised 340B Rebate Model Pilot Program, set to launch on January 1, 2027, with limited scope and conflict with MFP.
HRSA published a revised 340B Rebate Model Pilot Program, set to launch on January 1, 2027, with limited scope and conflict with MFP.
Source: Drug Channels
08
AAMC and AHA push for changes in 340B policies.
AAMC and AHA filed comment letters targeting CMS’ Medicare Drug Price Negotiation Program rule and Sen. Cassidy’s 340B Act draft.
AAMC and AHA filed comment letters targeting CMS’ Medicare Drug Price Negotiation Program rule and Sen. Cassidy’s 340B Act draft.
Source: Becker’s Hospital Review
09
Froedtert Memorial Lutheran Hospital lawsuit against CVS progresses.
The lawsuit filed by Froedtert Memorial Lutheran Hospital against CVS Health over 340B diversion is ongoing in the E.D. Wisconsin court.
The lawsuit filed by Froedtert Memorial Lutheran Hospital against CVS Health over 340B diversion is ongoing in the E.D. Wisconsin court.
Source: CourtListener
10
State of New York sues HHS over 340B program issues.
The State of New York filed a lawsuit against HHS in the D. Maryland court, challenging aspects of the 340B program.
The State of New York filed a lawsuit against HHS in the D. Maryland court, challenging aspects of the 340B program.
Source: CourtListener
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The recent court rulings and ongoing lawsuits highlight the contentious nature of the 340B program. Drugmakers are increasingly challenging the program’s implementation, while hospitals and clinics fight to maintain access to discounted drugs. This legal landscape creates uncertainty for covered entities and could lead to changes in how the 340B program is administered, potentially impacting patient access to affordable medications.
Emerging risks.
- Hospitals face financial risks from potential 340B program changes and increased repayment obligations.
- Legal battles over 340B policies could result in unfavorable rulings for covered entities.
- Drugmakers’ challenges to state laws may lead to restrictions on contract pharmacy arrangements.
- CMS’ proposed payment changes could reduce reimbursement rates for 340B-acquired drugs.
- Ongoing litigation may lead to increased compliance and operational costs for hospitals.
Emerging opportunities.
- Hospitals can engage in advocacy to influence CMS’ final rulemaking on 340B payment changes.
- Specialty pharmacies may benefit from clarifications in 340B reimbursement methodologies.
- Entities can explore partnerships to strengthen compliance with 340B program requirements.
- Healthcare groups can unite to challenge unfavorable 340B policy proposals.
- Organizations can use legal precedents to defend against drugmaker challenges.
Key actions for providers.
- Monitor ongoing litigation and court rulings related to the 340B program.
- Submit comments to CMS on proposed rules affecting 340B reimbursement and operations.
- Review compliance with 340B program requirements to mitigate decertification risks.
- Engage with legal counsel to address challenges from drugmakers and state laws.
- Participate in industry coalitions to advocate for favorable 340B policies.
TOP STORIES
Federal judge decertifies 11 clinics from 340B program.
Becker’s Hospital Review · August 20, 2026
- The U.S. District Court for the District of Columbia decertified 11 clinics from the 340B program.
- Drugmakers Amgen and Genentech won partial summary judgment against the clinics.
- The court ruled the clinics did not meet statutory requirements for 340B participation.
NASP comments on CMS’ proposed 340B payment changes.
NASP · September 1, 2026
- NASP submitted comments on CMS’ CY 2027 HOPPS proposed rule.
- The comments address Medicare reimbursement changes for 340B-acquired drugs.
- NASP highlighted implications for specialty pharmacy services and patient access.
Milwaukee hospital sues CVS over alleged 340B diversion.
Becker’s Hospital Review · August 31, 2026
- Froedtert Memorial Lutheran Hospital sued CVS Health for $18 million in alleged 340B diversion.
- The lawsuit names CVS Health, CaremarkPCS Health, and WellPartner as defendants.
- Froedtert alleges improper adjudication of 340B-eligible specialty drug claims.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
AHA urges CMS to reconsider 2027 outpatient rule proposals.
Becker’s Hospital Review · August 26, 2026
- AHA urged CMS not to finalize proposals that increase Medicare payment clawbacks.
- The proposed rule would cut 340B drug reimbursement rates.
- AHA warned the changes would cost hospitals significantly in 2027.
Hospital groups oppose CMS’ 2027 outpatient proposed rule.
Becker’s Hospital Review · August 31, 2026
- AHA, AAMC, and AMGA urged CMS to withdraw or scale back key provisions.
- The groups opposed 340B drug payment cuts and site-neutral payment expansion.
- They highlighted the financial strain on hospitals due to the proposed rule.
HRSA revises 340B Rebate Model Pilot Program.
Drug Channels · August 25, 2026
- HRSA published a revised 340B Rebate Model Pilot Program.
- The pilot program is set to launch on January 1, 2027.
- It has a limited scope and conflicts with the Maximum Fair Price.
STATE DEVELOPMENTS
Illinois Enacts 340B Protection Law
ACI Monthly – August 2026 · August 17, 2026
- Illinois signed HB 2371 into law, adding new state-level protections for covered entities and contract pharmacies.
- The law aims to safeguard the interests of 340B participants within the state.
- The legislation was enacted in August 2026.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| D.D.C. | Amgen and Genentech v. 11 Clinics, case decertified for 340B participation. [source] | August 20, 2026 |
| E.D. Wis. | Froedtert Memorial Lutheran Hospital Inc v. CVS Health Corporation [source] | August 20, 2026 |
| N.D. Ill. | ASTRAZENECA PHARMACEUTICALS LP v. KWAME RAOUL, in his official capacity as ATTORNEY GENERAL of the STATE OF ILLINOIS [source] | August 14, 2026 |
| D. Maryland | State of New York v. U.S. Department of Health and Human Services [source] | August 27, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
The following items were identified through a web search for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, including reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators.
AHA’s Concerns Over 340B Rebate Model’s Impact on Access to Care
American Hospital Association · August 2026
- Main theme: AHA’s opposition to the 340B rebate model and its potential negative effects.
- Stakeholder sentiment: The AHA strongly opposes replacing upfront 340B discounts with any rebate model, stating that such changes would shift financial risk to 340B covered entities and introduce significant administrative burdens.
- Potential implications: Implementation of a rebate model could undermine the statutory purpose of the 340B program and affect patient access to care.
- Credibility: The AHA is a reputable organization representing nearly 5,000 member hospitals and health systems.
AHA’s Response to 340B for Patients Act Discussion Draft
American Hospital Association · August 25, 2026
- Main theme: AHA’s feedback on proposed changes to the 340B program.
- Stakeholder sentiment: The AHA expresses concerns over provisions in the 340B for Patients Act that could narrow the definition of a 340B patient and impose eligibility limits on hospital off-site outpatient facilities, potentially reducing access to 340B savings.
- Potential implications: Proposed changes could limit hospitals’ ability to provide essential care to patients in need.
- Credibility: The AHA is a reputable organization representing nearly 5,000 member hospitals and health systems.
WHAT TO WATCH NEXT
- CMS to review comments on CY 2027 HOPPS proposed rule and finalize by end of 2026. [source]
- HRSA’s 340B Rebate Model Pilot Program to launch on January 1, 2027. [source]
- AstraZeneca’s lawsuit against Illinois’ 340B law to proceed in federal court. [source]
- Froedtert Memorial Lutheran Hospital’s lawsuit against CVS Health to continue in E.D. Wisconsin. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.